Waun Ki Hong

US Patent:

20130230511, Sep 5, 2013

Filed:

Feb 4, 2013

Appl. No.:

13/758728

Inventors:

Ignacio I. WISTUBA - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

G01N 33/74
A61K 39/395
A61K 31/506
A61K 31/4439
C12Q 1/68
A61K 31/4045

US Classification:

4241331, 435 723, 435 611, 514414, 51425218, 514338

Abstract:

Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.